Provisions governing hospital reimbursement for biological products to treat rare diseases modified.

Summary

The bill changes Minnesota law so hospitals get a distinct payment for biological products used in inpatient cell or gene therapy that treat rare diseases. The payment must equal the hospital’s actual acquisition cost, and it applies only when the drug maker has a value‑based agreement with the state commissioner. This aims to ensure hospitals are not financially penalized for providing these high‑cost therapies.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share